Latest news with #Adagio
Cision Canada
7 days ago
- Entertainment
- Cision Canada
NEW HORIZON FOR SINGER DIMASH Français
MONTREAL, July 24, 2025 /CNW/ - With an incomparable voice and a stage presence that captivates audiences worldwide, singer Dimash Qudaibergen is embarking on new artistic adventures across Europe and North America. The Stranger tour continues Following recent tour announcements, fans can now look forward to spectacular performances in Riga, Berlin, London, Barcelona,New York and Mexico between October and December. Dimash, from Kazakhstan, is looking forward to showcasing his art and dreams around the world. At meetings organized in London and Barcelona with fans and the press, the artist, composer, performer and multi-instrumentalist shared that he has a multitude of projects in mind. While he admits that the song "SOS d'un terrien en détresse" is the one that has accompanied him since the beginning of his career, he is multiplying compositions blending different genres and vocal techniques. Each concert is a chance to present new and unexpected material. With more than 20 years of musical training and experience, Dimash brings exceptional depth to his performances. Known for his vocal range of over six octaves and his ability to shift effortlessly between styles from classical to pop, he continues to challenge expectations. For him, consistent work and the support of his fans remain the key to lasting success. A surprise duet with Lara Fabian While in London, Dimash joined none other than Lara Fabian in concert to perform the legendary song Adagio. He described her as one of the singers he most admires for her artistry, humility, and professionalism. In turn, Lara Fabian called Dimash one of the most impressive voices she has ever heard. Their duet was a powerful moment marked by mutual respect and exceptional combined talents. Dimash being involved in film-videos, and performing pop, rock, folk and classical creations, has recently sung with maestro Placido Domingo and renowned cellist Hauser, testifying to his artistic versatility and his desire to explore music without boundaries. Without doubt, an artist to discover. Upcoming concerts New York October 5, 2025 Mexico October 8, 2025 Barcelona November 8, 2025 London November 12, 2025 Berlin November 14, 2025 Riga December 12, 2025
The Herald Scotland
26-06-2025
- Entertainment
- The Herald Scotland
A fitting end to the East Neuk Festival
Bowhouse, St Monans More usually it is the job of the Scottish Chamber Orchestra to close the East Neuk Festival at the Bowhouse, but that task has gone to an agglomeration of string quartets this year, so this marvellous menu of melodic orchestral music opened the programme, and the surprisingly fine acoustic of the big farm shed seemed even more startling as a result. At the heart of the concert was Rodrigo's Concierto de Aranjuez with Edinburgh's international guitar star Sean Shibe as the soloist. The work is not just the only guitar concerto everyone knows but has one of the most familiar openings of any concerto, one that immediately suggests the start of both the finale and the beautiful Adagio theme the soloist shares with the orchestra's cor anglais. Read More: Shibe's guitar was subtly amplified with a microphone and small PA to assure its place in the balance, and his relaxed, virtuosic playing – he must already have performed the piece countless times – was always clear but never over-dominant. Conductor Andrew Manze's sympathetic shaping of the music, ensuring that every detail of conversation between the guitar and the other players was heard, was just as essential to what was an immaculate account of the work. Manze brought the same expansive approach to Schubert's Symphony No 6 after the interval, his realisation of the variations of tempi and dynamics in the slow movement and following Scherzo bringing out all the symphony's youthful drama. His startlingly light touch in the finale emphasised its pastoral feel, which echoed the less well-known piece that had opened the concert. Lars-Erik Larsson is a 20th century contemporary of Rodrigo, and the Swede's Pastoral Suite, from immediately before the Second World War, is a three-movement concerto for orchestra of enormous charm. The SCO strings were on stellar form from the start, and its central Romance has lush scoring that invites comparison with Barber's Adagio and Mahler Five. The lively conclusion, featuring Andre Cebrian's flute and rhythmic pizzicato low strings, sounded close kin to the best mid-20th century British film scores. The 2025 East Neuk Festival had a memorable start, before the SCO played a note, when fiddler Donald Grant entered from the back of the barn and walked through the audience to preface Manze and Shibe's appearance onstage. That atmospheric opening trailed his playing in St Fillan's Cave in Pittenweem at the weekend when he and SCO cellist Su-a Lee soundtrack a new video installation by Andy McGregor.
Hospitality Net
27-05-2025
- Business
- Hospitality Net
Adagio Original London City East: Europe's Leading Aparthotel Brand Opens Innovative Flagship in the Heart of London
The Adagio Original London City East has just opened its doors, becoming Adagio's ninth establishment in the UK and the fourth in London for Europe's leading aparthotel brand. This new site stands out for its exceptional location, sleek modern design enhanced by exclusive artwork from a local artist, as well as several innovations, such as a new apartment furnishing concept and five coliving apartments. Offering the highest standards in hospitality, this new flagship features 132 studios and apartments, accommodating 1 to 8 guests. An ideal location, right in the heart of London Located right in the heart of London, just steps from the City and only a 5-minute walk from Aldgate East or Whitechapel tube stations, the Adagio Original London City East is perfectly situated for both business travellers and holiday makers exploring the British capital. Visitors will be able to enjoy the vibrant and multicultural atmosphere of Whitechapel, whilst also being just a ten-minute walk away from iconic landmarks such as the Tower of London, Tower Bridge, Brick Lane, and Old Spitalfields Market,. Innovative and modern, with a distinctly urban flair The Adagio Original London City East is located in a new building, with a striking design inspired by local culture, blending traditional red bricks with a clean and elegant aesthetic. The 132 studios and apartments showcase the new Adagio Original apartment concept, 'The Smart House', which offers guests the highest level of comfort. With open-plan spaces, warm hues, and multifunctional furniture, each apartment becomes a modern sanctuary - both calming and inspiring - quickly making guests feel right at home. The first introduction of 'Coliving by Adagio' in London Another distinctive feature of this new aparthotel is the inclusion of five 'Coliving by Adagio' suites. This concept has been specifically designed to accommodate groups, whether they are travelling for work, family trips, or holidays with friends. Designed to feel like a real apartment, each co-living suite consists of four independent studios, each equipped with its own bathroom and toilet, arranged around shared spaces, a fully equipped open kitchen for down time, and a welcoming shared living room. These fully furnished spaces are ideal for longer stays, thoughtfully designed to provide maximum comfort. Decor enhanced by local artwork In celebration of Whitechapel's vibrant visual and cultural spirit, the Adagio Original London City East has commissioned local artist, The Line Girl, to enhance its decor. Known for her distinctive graphic universe piece composed of black and white lines, the artist created an in- situ artwork that winds through the spaces: a large mural unfolding from the lobby to the lift and along the corridors on each floor. Her artwork travels through the hotel, creating an immersive visual journey for guests, transforming the space into a living canvas. Deeply connected to the neighbourhood, The Line Girl captures the culture and spirit of Whitechapel, whilst also creating subtle and encompassing art for guests to inhabit and admire. By integrating unique artworks into its spaces, Adagio enriches the guest experience, placing art at the heart of every stay. This approach, embraced by all new Adagio Original properties, champions an inclusive view of art: accessible, inspiring, and emotionally engaging. Hotel website
Business Wire
15-05-2025
- Business
- Business Wire
Adagio Medical Reports First Quarter 2025 Results
BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ('Adagio' or 'the Company'), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025. Recent Business Highlights: Received Breakthrough Device Designation from the U.S. Food and Drug Administration (the 'FDA') for the vCLAS™ Cryoablation System ('vCLAS'), for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ('VT') in patients with ischemic or non-ischemic structural heart disease. The vCLAS TM Cryoablation System is currently the subject of the FULCRUM-VT Investigational Device Exemption ('IDE') study designed to support FDA approval. The Breakthrough Device program allows for the FDA to potentially provide Adagio with priority review and interactive communication during the vCLAS TM review phase. Surpassed 50% enrollment in the FULCRUM-VT pivotal study. The study, which seeks to enroll 206 patients with ischemic and non-ischemic disease at 20 U.S. and Canadian centers, is on track for completion of patient enrollment in the second half of 2025. Adagio's Ultra-Low Temperature Cryoablation ('ULTC') and vCLAS technologies were showcased by leading electrophysiologists during multiple scientific sessions at the recent European Heart Rhythm Association (EHRA) and Heart Rhythm Society (HRS) industry meetings. Hired industry veteran Deborah Kaster, who has more than 25 years of leadership experience in the medical technology sector, as Chief Business Officer. Implemented a corporate prioritization initiative focusing all resources on the FULCRUM-VT clinical trial activities and the Company's new product design optimization program, which has been designed to advance faster innovation and iteration to meet market demands. 'This has been a defining quarter for Adagio Medical and for our progress across the company. The FDA's Breakthrough Device Designation, multiple impactful presentations at leading industry conferences, the introduction of our optimized smaller, faster next generation ULTC technology in development and the continued momentum in enrolling patients in our FULCRUM-VT trial all underscore the clinical promise and growing validation of our proprietary ULTC platform technology,' said Todd Usen, Chief Executive Officer of Adagio. 'I am so proud of the Adagio team's accomplishments as we remain resolute in our mission to transform patient treatment and outcomes with our purpose-built solution for the large, underserved population of patients suffering from ventricular tachycardia.' First Quarter 2025 Financial Results Cost of revenue was $0.3 million for the three months ended March 31, 2025, compared to $0.5 million for the three months ended March 31, 2024. Research and development expenses were $3.7 million for the three months ended March 31, 2025, compared to $3.5 million for the three months ended March 31, 2024. Selling, general and administrative expenses were $3.5 million for the three months ended March 31, 2025, compared to $4.8 million for the three months ended March 31, 2024. Net loss for the three months ended, March 31, 2025 was $7.7 million, or $(0.50) per share, compared to a net loss of $8.0 million, or $(10.28) per share, for the three months ended, March 31, 2024. Reported cash and cash equivalents of $13.0 million as of March 31, 2025. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS™ Cryoablation System which is CE Marked and is currently under evaluation in the Company's FULCRUM-VT U.S. IDE Pivotal Study. About FULCRUM VT FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio's vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT. Adagio's vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic ventricular tachycardia in Europe and select other geographies but is limited to investigational use in the United States. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' 'plans,' and 'future' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning: the potential of our vCLAS™ Cryoablation System; our research, development and regulatory plans for our product candidates, including the timing of initiating additional trials and reporting data from our trials; the regulatory pathway for our vCLAS™ Cryoablation System and the potential impacts of the Breakthrough Device Designation; the potential for our product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies; and our current cash resources and the impacts of our corporate prioritization initiative and realignment of resources. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ('SEC') filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2024, which is available on the SEC's website at Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law. Condensed Statements of Operations Three Months Ended March 31 2025 2024 Revenue $ — $ 26 Cost of revenue 253 542 Research and development 3,659 3,469 Selling, general, and administrative 3,485 4,830 Total cost of revenue and operating expenses 7,397 8,841 Loss from operations (7,397) (8,815) Other (income) expenses: Convertible notes fair value adjustment 190 1,673 Warrant liabilities fair value adjustment 38 (80) Interest expense (662) (754) Interest income 164 1 Other income (expense), net (46) (43) Total other income, net (316) 797 Net loss $ (7,713) $ (8,018) Basic net loss per share $ (0.50) $ (10.28) Diluted net loss per share $ (0.51) $ (10.28) Weighted-average shares outstanding, basic and diluted 15,375,521 779,908 Expand
Scroll.in
12-05-2025
- Entertainment
- Scroll.in
Start the week with a film: In ‘Last Night of Amore', the wages of temptation
Franco Amore is getting ready to quit the Milan police force after a 35-year stint. He has his retirement speech ready. He even has a post-retirement job waiting for him. What could go wrong? The timing, for one. Last Night of Amore (2023) is all about bad timing – the future boss who wants Franco to carry out a task even before he has officially ceased to be a cop, the wrong moves made during a routine drop, Franco's own haste to give his family the life he has never been able to afford. Andrea Di Stefano's stylish Italian thriller is out on Prime Video and can also be rented from BookMyShow Stream. The 124-minute film jumbles up its timeline, moving between a tense situation that unfolds over a single night and the events that lead to the standoff. Last Night of Amore pays visual homage to Stefano Sollima's moody neo-noir dramas about corruption and moral choices (among these, Adagio is available on Netflix). In the opening sequence of Last Night of Amore, cameras glide over Milan, eventually moving downwards into Franco's apartment, where his wife Viviana is waiting for him. The pursuit of the high life is what gets Franco into trouble. He has been running a side hustle by driving around his acquaintance Cosimo. When Cosimo proposes an assignment for the Chinese businessman Zhang, Franco signs up along with his colleague Dino (Francesco Di Leva). Franco's moment of truth – the realisation that he stands to lose his carefully built-up credibility – is incredibly shot and edited. Di Stefano's examination of the wages of temptation has a raft of sharp performances, especially by Linda Caridi as Franco's supportive spouse. Such films usually relegate female characters to the sidelines, but Caridi's Viviana proves indispensable to the plotting. Renowned Italian actor Pierfrancesco Favino, a veteran of crime thrillers, is terrific in the lead role. Favino, who also stars in Adagio, memorably portrays Franco's watchful ways and his fortitude when his luck turns rotten. The night is indeed long for Franco Amore, but it doesn't feel so in Pierfrancesco Favino's company. Play
